145 related articles for article (PubMed ID: 33876865)
21. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
[TBL] [Abstract][Full Text] [Related]
22. Examining the relationship between attention-deficit/hyperactivity disorder and overweight in children and adolescents.
Erhart M; Herpertz-Dahlmann B; Wille N; Sawitzky-Rose B; Hölling H; Ravens-Sieberer U
Eur Child Adolesc Psychiatry; 2012 Jan; 21(1):39-49. PubMed ID: 22120761
[TBL] [Abstract][Full Text] [Related]
23. Use of medication by young people with attention-deficit/hyperactivity disorder.
Sawyer MG; Rey JM; Graetz BW; Clark JJ; Baghurst PA
Med J Aust; 2002 Jul; 177(1):21-5. PubMed ID: 12088474
[TBL] [Abstract][Full Text] [Related]
24. The relationship between chronotype and obesity in children and adolescent with attention deficit hyperactivity disorder.
Türkoğlu S; Çetin FH
Chronobiol Int; 2019 Aug; 36(8):1138-1147. PubMed ID: 31177853
[TBL] [Abstract][Full Text] [Related]
25. Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents.
Baweja R; Hale DE; Waxmonsky JG
CNS Drugs; 2021 Aug; 35(8):839-859. PubMed ID: 34297331
[TBL] [Abstract][Full Text] [Related]
26. Neurobehavioral phenotypes of delay discounting and cognitive control in child attention-deficit/hyperactivity disorder and obesity: Shared or distinct?
Thapaliya G; Carnell S; Mostofsky SH; Rosch KS
Pediatr Obes; 2023 Apr; 18(4):e13001. PubMed ID: 36655309
[TBL] [Abstract][Full Text] [Related]
27. [Frequency of overweight and obesity in children and adolescents with autism and attention deficit/hyperactivity disorder].
Kummer A; Barbosa IG; Rodrigues DH; Rocha NP; Rafael Mda S; Pfeilsticker L; Silva AC; Teixeira AL
Rev Paul Pediatr; 2016; 34(1):71-7. PubMed ID: 26525687
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
29. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample.
Waring ME; Lapane KL
Pediatrics; 2008 Jul; 122(1):e1-6. PubMed ID: 18595954
[TBL] [Abstract][Full Text] [Related]
30. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of obesity and overweight among Chinese children with attention deficit hyperactivity disorder: a survey in Zhejiang Province, China.
Yang R; Mao S; Zhang S; Li R; Zhao Z
BMC Psychiatry; 2013 May; 13():133. PubMed ID: 23663690
[TBL] [Abstract][Full Text] [Related]
32. Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses.
Ross L; Sapre V; Stanislaus C; Poulton AS
CNS Drugs; 2020 Jun; 34(6):643-649. PubMed ID: 32300972
[TBL] [Abstract][Full Text] [Related]
33. Associations between Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Patient Nutritional Status and Height.
Granato MF; Ferraro AA; Lellis DM; Casella EB
Behav Neurol; 2018; 2018():7341529. PubMed ID: 30386441
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and Correlates of Attention-Deficit Hyperactivity Disorder in a Diverse, Treatment-Seeking Pediatric Overweight/Obesity Sample.
Merrill BM; Morrow AS; Sarver D; Sandridge S; Lim CS
J Dev Behav Pediatr; 2021 Aug; 42(6):433-441. PubMed ID: 34397571
[TBL] [Abstract][Full Text] [Related]
35. Attention deficit hyperactivity disorder medications and BMI trajectories: The role of medication type, sex and age.
Gurka MJ; Siddiqi SU; Filipp SL; Mercado R; Thompson LA; Janicke DM; Shenkman EA
Pediatr Obes; 2021 Apr; 16(4):e12738. PubMed ID: 33064373
[TBL] [Abstract][Full Text] [Related]
36. Risk of Overweight and Obesity in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
Zhu Y; Wang NN; Pan D; Wang S
Child Obes; 2024 Mar; 20(2):119-127. PubMed ID: 36952326
[TBL] [Abstract][Full Text] [Related]
37. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
[TBL] [Abstract][Full Text] [Related]
38. [Impulsivity and obesity in children with Attention Deficit Hyperactivity Disorder: A clinical, neuropsychological and magnetic resonance spectroscopy exploratory study].
Ben Amor L; Lachal J
Encephale; 2019 Dec; 45(6):494-500. PubMed ID: 31492416
[TBL] [Abstract][Full Text] [Related]
39. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Overweight and Obesity in Children and Adolescents With ADHD: The Significance of Comorbidities and Pharmacotherapy.
Racicka E; Hanć T; Giertuga K; Bryńska A; Wolańczyk T
J Atten Disord; 2018 Oct; 22(12):1095-1108. PubMed ID: 25895508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
